The company has reported interim data from the pivotal phase 3 trial assessing Keytruda as both monotherapy and in combination with chemotherapy for the first-line treatment of recurrent
The post Merck’s Keytruda improves overall survival in head and neck cancer trial appeared first on Pharma Business review.